A detailed history of American Portfolios Advisors transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, American Portfolios Advisors holds 1,031 shares of GALT stock, worth $2,969. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,031
Holding current value
$2,969
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$1.31 - $2.48 $1,350 - $2,556
1,031 New
1,031 $1.68 Million
Q3 2019

Mar 24, 2023

BUY
$3.0 - $4.05 $1,500 - $2,025
500 Added 94.16%
1,031 $3.78 Million
Q2 2019

Mar 24, 2023

SELL
$3.61 - $5.0 $1,805 - $2,500
-500 Reduced 48.5%
531 $2.2 Million

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $171M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.